Making Sure the Cells Coming Back Are Yours Vein to Vein Tracking for CAR T Therapy

This application covers a computerised system for running a patient-specific immunotherapy procedure while maintaining an unbroken chain of custody and chain of identity for the patient’s own cells. A patient-specific identifier is generated when the cells are ordered and then travels with the sample through collection, shipping, manufacture, return shipping and infusion, with a timestamped tracking event recorded at each step. The applicant is Kite Pharma, the Gilead subsidiary behind the CAR T therapies Yescarta and Tecartus.

The Problem

CAR T cell therapy is not a drug in the ordinary sense. T cells are collected from one specific patient by leukapheresis, shipped to a manufacturing facility, genetically modified so they carry a chimeric antigen receptor that recognises the patient’s cancer, expanded, cryopreserved, shipped back, and infused into that same patient. Nothing about the product is interchangeable. There is no substitute vial on the shelf, and there is no second chance if the material is lost or mixed up, because the starting material was a critically ill person’s own immune cells.

That creates a requirement pharmaceutical logistics is not naturally built for. Ordinary drug supply chains track lots. An autologous cell therapy has to track a lot of exactly one, and it has to prove, at every handoff, that the container in front of the technician holds the cells of the patient whose name is on the infusion order. This is the distinction the specification draws between chain of custody, meaning an auditable record of who held the material and when, and chain of identity, meaning continuous proof that the material still belongs to the patient it came from.

The second pressure is time. Patients referred for CAR T therapy are usually out of other options, and the manufacturing turnaround, commonly discussed in the field as the vein to vein time, runs to weeks. Every day of delay carries clinical consequence. The specification notes plainly that existing systems lacked a technological solution for maintaining chain of custody and chain of identity, and that the resulting delays in the manufacturing process matter for exactly the patients least able to absorb them.

The third problem is that nobody could see the process. A patient, a treating physician, an apheresis centre and a manufacturing site each held one fragment of the picture, typically by phone and email. Without a shared record, the simple question of where the cells are today had no fast answer.

What This Invention Does

The system starts with an identifier. When a cell order request is received for a patient, a computing device generates a patient-specific identifier tied to that request, identifying both the patient and the cell order lot, and creates a corresponding data record in a database keyed to that identifier. From that point the identifier is the spine of the whole procedure.

The process it then drives is the clinical one, instrumented. Leukapheresis is performed on the patient’s blood to collect T cells; the collected cells are transferred to a container; the container is labelled with the patient-specific identifier; the cells are transmitted to a manufacturing facility; transfected T cells are created using a cell modification technique, such as transducing the collected cells with a polynucleotide encoding a chimeric antigen receptor; the transfected cells are received back; and they are infused into the patient’s bloodstream. At each of those steps the computing device records a tracking event containing the patient-specific identifier, a timestamp and an event identifier, and updates the data record accordingly.

Crucially, the tracking events come from the sites themselves rather than from a central operator typing them in later. Claims describe an event tracking module receiving a first tracking event from a client device located at the point of the leukapheresis procedure confirming the procedure and containing the patient-specific identifier, then further events as the cells are readied for shipment, manufactured, returned and infused, each integrated into the data structure for that identifier with its own timestamp. The result is a continuous and automatic record rather than a reconstructed one.

On top of the record sits a portal. Client devices belonging to the patient, the treating physician, the apheresis site and the manufacturing facility connect over a network to a server that presents chain of custody views through a graphical user interface. The disclosure is unusually specific about the plumbing, describing an implementation built on the Salesforce platform with Heroku, document execution through DocuSign, single sign-on via SAML 2.0, a scheduling module that supplies estimated delivery dates for the sample, and a physician master data feed drawn from a Veeva CRM integration.

Key Features

• Patient-specific identifier issued at order. The identifier is generated when the cell order request is received and identifies both the patient and the cell order lot, becoming the key for every subsequent record.
• Labelled container as the physical link. The collection container is labelled with the same identifier, tying the physical sample to the digital record from the moment the cells leave the patient.
• Timestamped tracking event at every step. Each of leukapheresis, shipment to manufacturing, transfection, return receipt and infusion generates a tracking event carrying the identifier, a timestamp and an event identifier.
• Events reported from the point of work. Tracking events are received from client devices located where the step actually happens, including the apheresis site and the manufacturing facility, rather than entered centrally after the fact.
• Shared status portal. A web portal gives the patient, physician, manufacturer and other medical personnel a common view of the current phase of the procedure and the status of the sample.
• Built on commodity enterprise software. The described implementation runs on general purpose platforms including Salesforce, Heroku and Veeva rather than bespoke laboratory information systems.

Who Is Behind It

Kite Pharma, Inc. is a biopharmaceutical company based in Santa Monica, California, acquired by Gilead Sciences in 2017 for approximately 11.9 billion dollars and now operating as a Gilead company. Its cell therapy portfolio includes Yescarta, approved in 2017 for large B-cell lymphoma, and Tecartus, approved in 2020 for mantle cell lymphoma. The priority filings here date from September and October 2017, which places this work at the point where Kite moved from clinical trial logistics to commercial manufacture at scale.

The named inventors are Debra Susarchick, John Uhrin and Michele Korfin. The mix is telling: this is not a molecular biology filing but an operations and commercial one, describing the information system that has to exist around a therapy before it can be delivered routinely by hospitals that did not build it.

The application is a divisional of Australian application 2023201386, itself a divisional of 2018334279, and claims priority from United States provisional applications 62/559,330 filed on 15 September 2017 and 62/566,912 filed on 2 October 2017.

Why It Matters

Autologous cell therapy has created a category of medicine where the supply chain is part of the product. A conventional biologic can be made in bulk, released against a specification and shipped anywhere. A CAR T dose exists for one person, cannot be remade if lost, and is judged partly on how quickly it can be returned. Manufacturers have competed openly on turnaround time, and Kite has publicised process changes aimed at reducing median vein to vein time. Software that removes days of coordination friction is therefore a clinical variable, not just an administrative one.

Regulators treat it that way too. The US Food and Drug Administration regulates these products under its framework for cellular and gene therapies, where labelling, traceability and prevention of mix-ups are explicit requirements rather than good practice. A tracking system that is continuous, automatic and auditable is compliance infrastructure. That is also why the chain of custody framing, borrowed from forensic and legal practice, appears in a patent about cancer treatment.

As a filing strategy, patenting the logistics layer of a therapy rather than the therapy itself is a deliberate and increasingly common move. The molecule is protected by its own patents; the operational system is what a competitor entering the same treatment centres would otherwise have to replicate. Carrying a 2017 priority through two divisionals to a 2026 application keeps the claim scope in that layer live for as long as the underlying products are on the market.

Related Concepts

• Chimeric antigen receptor T cell – the therapy class whose manufacture this system tracks.
• Apheresis – the blood collection procedure that begins the tracked chain.
• Chain of custody – the evidentiary concept the system applies to a biological sample.
• Cancer immunotherapy – the broader treatment field the procedure sits within.
• Axicabtagene ciloleucel – the applicant’s lead CAR T product, marketed as Yescarta.
• Kite Pharma – the applicant and one of the largest commercial cell therapy manufacturers.

---

AU 2026202096 was published in the Australian Official Journal of Patents on 9 April 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.